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Between January 1989 and August 1992, 612 CarboMedics mechanical 
prostheses (CarboMedics, Inc., Austin, Tex.) (295 mitral, 308 aortic, and 9 
tricuspid) were implanted in 504 patients: 189 patients had isolated mitral 
valve replacement, 209 had isolated aortic valve replacement, and 106 had 
multiple valve replacement. The total follow-up was 1182 patient-years. The 
hospital mortality rate was 7.4% for mitral valve replacement, 5.3% for 
aortic valve replacement, and 13.2% for multiple valve replacement. 
Linearized rates for the different complications for mitral valve replace- 
ment, aortic valve replacement, and multiple valve replacement (in events 
per 100 patient-years) were, respectively, as follows: late mortality, 2.6 -+ 
0.8, 1.5 _ 0.5, and 3.9 + 1.3; thromboembolim, 3.7 +- 0.9, 3.1 - 0.8, and 3.9 
+_ 1.3; valve thrombosis, 0.5 - 0.3 for mitral valve replacement and 0.4 ___ 
0.4 for multiple valve replacement; anticoagulant-related h morrhage, 2.8 
- 0.8, 1.9 +- 0.6, and 2.6 - 1.1; nonstructural dysfunction, 1.6 - 0.6, 0.8 - 
0.4, and 3.5 -+ 1.2; and reoperation, 1.1 - 0.5, 0.4 - 0.3, and 3.1 - 1.1. 
Actuarial estimates of freedom from the different complications for mitral 
valve replacement, aortic valve replacement, and multiple valve replace- 
ment (at 5 years of follow-up for mitral valve replacement and aortic valve 
replacement and 4.5 years for multiple valve replacement) were, respec- 
tively, as follows: overall death, 83% - 4%, 89% --- 2%, and 76% _ 4%; 
thromboembolism or valve thrombosis, 88% - 3%, 91% - 2%, and 86% +- 
5%; anticoagulant-related h morrhage, 89% - 3%, 95% --- 2%, and 90% - 
5%; nonstructural dysfunction, 97% -+ 1%, 98% -+ 1%, and 91% • 3%; and 
reoperation, 96% - 2%, 99% +-. 1%, and 87% +- 5%. There were no instances 
of prosthetic structural dysfunction. The performance of the CarboMedics 
valve is satisfactory at 5 years of follow-up but thromboembolic and 
hemorrhagic phenomena are still serious complications of mechanical 
prostheses. (J Thorac Cardiovasc Surg 1996;112:59-68) 
B ileaflet mechanical heart valves have demon- 
strated, during the past 16 years, their superiority 
over previous designs in terms of lower transvalvular 
gradients, a more physiologic flow pattern distribu- 
tion, and, possibly, a lower thrombogenic potential. 1 
A valve design based on two occluders, as opposed 
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to a single occluder, should provide, in theory at 
least, greater functional safety although it entails the 
use of a double hinge mechanism. Clinical experi- 
ence with the St. Jude Medical valve (St. Jude 
Medical Inc., St. Paul, Minn.) has shown a low rate 
of structural failure and thrombotic complica- 
tions. 2-s 
The CarboMedics bileaflet valve, manufactured 
by a company with a vast experience in the produc- 
tion of pyrolytic arbon (CarboMedics, Inc., Austin, 
Tex.), was approved for clinical use by the Spanish 
authorities in 1987. Its main advantage over other 
bileaflet models was the possibility of rotation once 
implanted, achieved by means of a new sewing ring 
design. 
The aim of the current study was to analyze the 
short-term performance of the CarboMedics valve. 
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Table I. Associated operations 
Procedures MVR A VR Multi VR 
Mitral valve repair 0 6 0 
LA thrombectomy/ligation 22 2 7 
of appendage 
Tricuspid valve repair 30 1 10 
Aortic operation 0 13 3 
Coronary artery operation 7 7 1 
Other 2 1 4 
LA, Left atrial. 
Table II. Demographics 
Age Gender 
Group Mean SD Range Male Female 
MVR 54.5 10.5 20-75 65 (34%) 124 (66%) 
AVR 54.1 11.1 15-74 155 (74%) 54 (26%) 
MultiVR 54.7 9.5 29-75 47 (44%) 59 (56%) 
SD, Standard deviation. 
For this purpose, we conducted the following single- 
center, observational, retrospective, and patient- 
oriented survey. 
Patients and methods 
Between January 1989 and August 1992, 504 consecu- 
tive patients received a total of 612 CarboMedics mechan- 
ical valves in our unit. Mitral valve replacement (MVR) 
was done in 189 patients, aortic valve replacement (AVR) 
in 209 patients, and multiple valve replacement (Mul- 
tiVR) in 106 patients (mitral and aortic valve replacement 
in 97 patients, mitral and tricuspid valve replacement in 7 
patients, and trivalvular eplacement in 2 patients). The 
total number of valves implanted was 295 in the mitral 
position, 308 in the aortic position, and 9 in the tricuspid 
position. All patients were operated on with the use of 
extracorporeal circulation and moderate hypothermia. 
Myocardial protection was achieved with the antegrade 
infusion of either hematic or crystalloid cardioplegic 
solution and topical cooling with cold saline solution. 
Concomitant procedures are shown in Table I. 
Anticoagulation with oral acenocoumarol was started in 
all cases as soon as the patient was capable of oral intake. 
After discharge from the hospital, the patients were 
referred to their local anticoagulation clinics with the 
recommendation to maintain an international normalized 
ratio (INR) of 2.5 to 3. 
We reviewed the data in the manner of a patient- 
oriented retrospective study. Data were collected uring 
the regular visits of the patients to the outpatient clinic, 
from the medical records, or by telephone interview. The 
closing interval was 6 weeks and the follow-up was 97% 
complete, with information lacking from 15 patients. All 
patients included in the study who survived and did not 
undergo reoperation had a minimum follow-up of 12 
months. 
Table I IL  Cause of valvular disease 
Cause MVR AVR MultiVR 
Rheumatic 11 (59%) 51 (24%) 51 (48%) 
Degenerative - -  99 (47%) - -  
Prosthetic dysfunction 59 (31%) 47 (22%) 46 (43%) 
Infective 5 (2%) 10 (5%) 4 (4%) 
Ischemic 4 (2%) - -  1 (1%) 
Other 10 (5%) 2 (1%) 4 (4%) 
The guidelines of the liaison committee of the AATS- 
STS-EACTS* for reporting morbidity and mortality after 
cardiac valvular operations were followed. 6
Complications that appeared with a nonbiased time 
course were expressed by means of linearized rates. 
Actuarial analysis was done by the Kaplan-Meier meth- 
od. 7 Comparison between actuarial estimates was done by 
use of normal distribution. Continuous variables were 
compared by a two-tailed Students t test. Categorical data 
were compared by a 2 × 2 contingency table or a X 2 test, 
corrected if appropriate by Yates' formula or Fisher's 
exact est. Assessment for p eoperative risk factors of the 
main postoperative complications was done, when the 
number of events was sufficient, by bivariate analysis (with 
Mann-Whitney or X 2 tests, corrected if necessary) and 
with multivariate analysis by means of stepwise logistic 
regression analysis or Coxs proportional hazards regres- 
sion model. Values of relative risk (RR) or odds ratios are 
given herein, together with 95% confidence limits (CL). 
Significance l vels lower than 0.05 were considered mean- 
ingful. 
Results 
The mean age of the patients was 54 years for 
MVR, AVR,  and MultiVR, with a range of 15 to 75 
years for the complete group (Table II). The patient 
was female in 66% of MVR, 26% of AVR,  and 56% 
of Mult iVR cases (Table II). The cause of the 
valvular disease (Table III) was predominantly rheu- 
matic among patients with mitral and multivalvular 
disease and degenerative in the aortic group. Re- 
placement of a failing prosthesis (bioprostheses 
in most cases) constituted the indication for opera- 
tion in 31% of MVR, 22% of AVR,  and 43% of 
Mult iVR recipients. 
The most common implantation valve sizes were, 
in order of frequency, 29, 31, and 27 mm for MVR; 
21, 23, and 25 mm for AVR,  and 31 mm for tricuspid 
valve replacement. 
The total follow-up was 1182 patient-years: 431 
patient-years in the MVR group, 522 patient-years 
in the AVR group, and 228 patient-years in the 
*The American Association f r Thoracic Surgery, Society of 
Thoracic Surgeons, and European Association of Cardiotho- 
racic Surgery. 
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Table IV. Hospital mortafity 
Causes MVR A VR MultiVR 
Low cardiac output 7 4 4 
Hemorrhage 4 3 6 
AMI 1 1 1 
Stroke 0 1 0 
Tamponade 1 0 0 
Sepsis 0 1 0 
Endocarditis 0 0 1 
Multiorgan failure 1 0 1 
Unknown 0 1 1 
AMI, Acute myocardial infarction. 
Table V. Late mortality 
Causes MVR A VR MultiVR 
Congestive HF 4 1 4 
Stroke 2* 2 0 
Embolism 1 0 0 
AMI 1 0 0 
Respiratory failure 1 0 0 
Endocarditis 0 0 1 
Sudden death 2 3 3 
Other 0 2 1 
HF, Heart failure; AMI, acute myocardial infarction. 
*One hemorrhagic and one thromboembolic. 
MultiVR group, with a mean follow-up of 2.5 years 
per patient for each of the cohorts. 
Mortality. The hospital mortality rate (within 30 
days of operation or before hospital discharge) was 
7.7% (39 patients) for the complete group: 7.4% (14 
patients) for MVR, 5.3% (11 patients) for AVR, 
and 13.2% (14 patients) for MultiVR. Hospital 
deaths were most commonly caused by periopera- 
tive hemorrhage or low cardiac output syndrome 
(Table IV). Three deaths were caused by embolic 
phenomena (1 stroke, 2 embolic myocardial infarc- 
tions). Statistically significant preoperative predic- 
tors of hospital mortality, for the whole population 
of patients, included atrial fibrillation (p -- 0.012, 
RR 2.9, 95% CL 1.3 to 6.7), cause of disease (p = 
0.012, RR 1.4, 95% CL 1.1 to 1.7), New York Heart 
Association functional class (p = 0.03, RR 1.7, 95% 
CL 1.1 to 2.7), and associated surgical procedures 
(p = 0.04, RR 1.3, 95% CL 1.0 to 1.6). For patients 
with isolated mitral valve disease the only significant 
predictor in the multivariable analysis was the func- 
tional class (p = 0.005, RR 4.3, 95% CL 1.5 to 11.8), 
and for the group with isolated aortic valve disease 
the only significant predictor was atrial fibrillation 
(p = 0.02, RR 5.2, 95% CL 1.3 to 19.8). Hospital 
mortality because of low cardiac output was signifi- 
cantly associated, for the whole cohort of patients, 
with a higher functional class (p = 0.006, RR 2.9, 
95% CL 1.4 to 6.3) and associated surgical maneu- 
vers (p < 0.05, RR 1.4, 95% CL 1.0 to 1.7). 
Twenty-eight patients died late after operation: 
11 in the MVR group, 8 in the AVR group, and 9 in 
the MultiVR group. Late deaths were most often of 
valvular or cardiac origin (Table V). Fatal embolic 
complications appeared in 4 patients (3 strokes and 
1 peripheral embolism). Linearized rates for late 
death were 2.6 _+ 0.8 deaths/100 pt-yr for MVR, 1.5 
_+ 0.5 for AVR, and 3.9 -+ 1.3 for MultiVR. Actu- 
arial survival estimates (including hospital mortal- 
ity) were 83% _+ 4% for MVR and 89% _+ 2% for 
AVR at 5 years and 76% _+ 4% for MultiVR at 4.5 
years (Fig. 1). A higher preoperative functional class 
was a significant predictor for late mortality, consid- 
ering the whole population of patients (p = 0.03, 
odds ratio 1.8, 95% CL 1.0 to 3.0). 
There were a total of 21 valve-related deaths in 
the complete group: 5 in the MVR group, 9 in the 
AVR group, and 7 in the MultiVR group. The 
linearized rates for valve-related death were 1.2 _+ 
0.5 events/100 pt-yr for MVR, 1.7 _+ 0.6 for AVR, 
and 3.1 _+ 1.2 for MultiVR. Actuarial estimates of 
freedom from valve-related mortality were 96% _+ 
2% for MVR and 94% _+ 2% for AVR at 5 years of 
follow-up and 91% _+ 3% for MultiVR at 4.5 years 
of follow-up (Fig. 2). 
Thromboembolism and valve thrombosis. Overall, 
there were 41 thromboembolic events in 38 patients 
(Table VI). The linearized embolic rates were 3.7 _+ 
0.9 events/100 pt-yr for MVR, 3.1 _+ 0.8 for AVR, 
and 3.9 _+ 1.3 for MultiVR. The rates for death 
caused by thromboembolic events were 0.5 +_ 0.3 
deaths/100 pt-yr for MVR, 0.8 -+ 0.4 for AVR, and 
0.4 _+ 0.4 for MultiVR. Rates for permanent impair- 
ment of embolic origin were 1.2 _+ 0.5 events/100 
pt-yr for MVR, 1.0 + 0.4 for AVR, and 1.7 _+ 0.9 for 
MultiVR. Age was a significant preoperative predic- 
tor of thromboembolism after operation for the 
total cohort of patients (X 2 = 5.12, p = 0.02). 
Three episodes of valve thrombosis were re- 
corded. The three patients underwent reoperation 
and the prostheses were replaced (by two biopros- 
theses and one similar mechanical valve) with one 
resulting death. The linearized rates for thrombosis 
were 0.5 +- 0.3 events/100 pt-yr for MVR and 0.4 _+ 
0.4 for MultiVR (Table VI). 
Actuarial probabilities of freedom from thrombo- 
embolism or valve thrombosis (Fig. 3) were 88% __ 
3% for MVR and 91% _+ 2% for AVR at 5 years of 
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Fig. 1. Overall mortality (including hospital and late mortality): actuarial analysis. 
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Fig. 2. Valve-related mortality: actuarial analysis. 
follow-up and 86% + 5% for MultiVR at 4.5 years 
of follow-up. 
Anticoagulant-related hemorrhage. There were 
28 significant hemorrhagic events in 25 patients that 
necessitated a mission of the patient o the hospital, 
with or without ransfusion. The linearized rates for 
this complication were 2.8 _+ 0.8/100 pt-yr for MVR, 
1.9 _+ 0.6 for AVR, and 2.6 _+ 1.1 for MultiVR 
(Table VI). One patient with mitral valve disease 
died as a result of an intracerebral hemorrhage. The 
actuarial estimates of freedom from significant hem- 
orrhagic omplications (Fig. 4) were 89% _+ 3% and 
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Fig. 3. Thromboembolism and valve thrombosis: actuarial analysis. 
Table VI. Complications 
MVR A VR Multi VR 
Patients Events LR Patients Events LR Patients Events LR 
Thromboembol i sm 14 16 3.7 _+ 0.9 
Valve thrombosis 2 2 0.5 +_ 0.3 
Hemorrhage  12 12 2.8 + 0.8 
Endocardi t is  - -  - -  
Nonstructural  dysfunction 6 7 1.6 ± 0.6 
Reoperat ion  5 5 1.1 ± 0.5 
16 16 3.1 +- 0.8 8 9 3.9 -+ 1.3 
- -  - -  1"  1 0.4 +- 0.4 
8 10 1.9 ± 0.6 5 6 2.6 -+ 1.1 
- -  - -  2 2 0.9 + 0.6 
3 4 0.8 -+ 0.4 7 8 3.5 ± 1.2 
2 2 0.4 ± 0.3 7 7 3.1 ± 1.1 
LR, Linearized rate (in events per 100 p-y) plus or minus standard error. 
*Thrombosis on tricuspid valve. 
95% _+ 2% for MVR and AVR, respectively, at 5 
years and 90% +_ 5% for MultiVR at 4.5 years of 
follow-up. 
Nonst ructura l  dysfunct ion.  Nineteen instances 
of nonstructural dysfunction (hemolysis or peripros- 
thetic leak, or both) were evidenced in 16 patients 
(Table VI). Overall, there were five cases of hemo- 
lysis, which includes those of two patients who 
showed clinical hemolysis without demonstrated 
periprosthetic leak. 
Linearized rates for dysfunction were 1.6 _ 0.6 
events/100 pt-yr for MVR, 0.8 __ 0.4 for AVR, and 
3.5 _+ 1.2 for MultiVR. Actuarial analysis revealed 
probabilities of freedom from this complication of 
97% _+ 1% for MVR and 98% + 1% for AVR at 5 
years and 91% +_ 3% for MultiVR at 4.5 years of 
follow-up (Fig. 5). 
Prosthet ic  endocardit is .  Two cases of endocardi- 
tis were detected in two patients from the MultiVR 
group (Table VI). One of them underwent reopera- 
tion and died 2 months later of recurrent valve 
infection. The other patient died of septicemia 
before operation could be done. 
Reoperation. A total of 14 patients required re- 
operation: 5 in the MVR group, 2 in the AVR 
group, and 7 in the MultiVR group (Table VI). The 
reasons for reoperation were periprosthetic leak in 8 
patients (1 in MVR group, 2 in AVR group, and 5 in 
MultiVR group), valve thrombosis n 3 (2 in MVR 
group and 1 in MultiVR group), and prosthetic 
endocarditis n 1 patient with combined mitral and 
aortic valvular disease. Two other patients with 
mitral disease, with normally functioning prostheses, 
underwent reoperation because of severe tricuspid 
64 Nistal et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
July 1996 
E 100%, 
o 
"o 98% 
t . _  
IJ= 96% 
N, , -  
O 
>~ 94% 
JO 92% 
.¢1 
O 90% 
I , ,=  
¢L 
"~ 88% .... 
86% 
dkd 
o 
~.~ - _ 
- -  • ' " ' " -n+.  \ \  
..+,v, i \' i , ,1_9o±5 
t - -Mu l t iVR  t • ~ 
_" ~ _ 89 
189 153 116 65 I 26  
-=209 185 144 88 34 
1106 83 61 39 .17  
I I I I I F [ I I 
0 1 2 3 4 5 
Postoperative Years 
Fig. 4. Anticoagulant-related hemorrhage: actuarial analysis. 
100% ~.  ~. 
+o o . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  98++I . ,  +,8+ , . .  ..... I 
" " , " - . .  ° I 
O 96% 
=(,=l  
JQ 94% 0= 
O 
L_  
D. 92% 
! , _  
O3 90% 
U <¢ 
'-. 97_+1 
AVR ,, 91 _+3 
Multi VR ~ . . . . . . . . . . . . . . . .  
189 157 121 68  27  5 
~209 189 149 91 36 9 
106 84 61 38 17 
I I I I F I P I I 
1 2 3 4 
Postoperative Years 
Fig. 5. Nonstructural dysfunction: actuarial analysis. 
insufficiency and for a heart transplantation, respec- 
tively. There were three cases of reoperation-related 
death: one MVR recipient with a thrombosed pros- 
thesis, one AVR recipient who underwent reopera- 
tion because of a periprosthetic leak, and one 
MultiVR recipient with prosthetic endocarditis. 
Linearized reoperation rates were 1.1 _+ 0.5 
events/100 pt-yr for MVR, 0.4 + 0.3 for AVR, and 
3.1 + 1.1 for MultiVR. The actuarial probabilities of 
freedom from reoperation were 96% _+ 2% and 
99% - 1% for MVR and AVR at 5 years and 87% 
+ 5% for MultiVR at 4.5 years of follow-up (Fig. 6). 
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Structural dysfunction. No cases of reoperation 
or death were recorded as the result of structural 
dysfunction. There was no clinical evidence of in- 
trinsic valve failure in any patient in this study. 
Functional status and valve-related morbidity 
and mortality. More than 80% of the patients in the 
MVR and MultiVR groups and nearly 50% in the 
AVR group had New York Heart Association class 
III or IV disease before operation. Postoperative 
functional class was I or II in at least 90% of the 
patients in each of the cohorts. However, small 
groups of patients with class III or IV symptoms 
persist, particularly in the MVR and MultiVR 
groups (Table VII). 
Actuarial estimates of freedom from any valve- 
related morbidity or mortality were 68% _+ 4% and 
79% _+ 3% for MVR and AVR at 5 years and 62% 
_+ 6% at 4.5 years of follow-up for MultiVR (Fig. 7). 
A significant difference (p < 0.05) between the AVR 
and the MultiVR curves is noted after the second 
year of follow-up. 
Discussion 
Bileaflet design of mechanical heart valve pros- 
theses dates back at least o 1964 and 1969, when the 
Gott-Daggett and the Kalke-Lillehei devices were 
described.S, 9 Both of these prosthetic designs failed 
as a result of thrombotic phenomena, even though 
Dr. Gotts valve had, as an innovative technical 
Table VII. Functional class before and after 
operation 
MVR A VR Multi VR 
Preop. Postop. Preop. Postop. Preop. Postop. 
NYHAclass  (%) 
I 1 64 14 77 7 61 
II 14 26 38 19 12 29 
III 65 10 34 4 59 8 
IV 20 - -  14 - -  22 2 
NYHA, New York Heart Association. 
characteristic, a treatment of the leaflets with pyro- 
lytic carbon (graphite) that would supposedly pre- 
vent these complications. The experimental nd 
clinical success of this design had to wait until the 
mid-1970s, when the technology of pyrolytic arbon 
was well established. In 1979, Emery, Mettler, and 
Nicoloff 1° reported the first series of clinical im- 
plants of the St. Jude Medical valve, with excellent 
early results in terms of thromboembolism and 
hemodynamics. Several other groups have delin- 
eated the in vitro and in vivo hemodynamic charac- 
teristics of this prosthesis and have reported its 
clinical follow-up, which currently goes beyond the 
15-year mark. 2s' 11-15 
In 1987 the CarboMedics heart valve prosthesis 
was approved for clinical use in Spain, and late in 
1993 the Food and Drug Administration authorized 
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the use of this implant in the United States. The 
main advantage of this device over previous bileaflet 
designs was the possibility of rotating the cage 
against he sewing ring after the valve was in posi- 
tion. This feature would, theoretically, help avoid 
interference of valve remnants or other structures 
with the valve mechanism and would be of particular 
interest when this device was implanted on nonre- 
sected atrioventricular valves. 16 On the other hand, 
its in vitro and in vivo hydrodynamic characteristics 
have been shown to be comparable to those of the 
St. Jude Medical prosthesis. 15' 17, ~s 
The current study is a single-institution study, 
which is, in our opinion, the best way to analyze the 
performance of a prosthetic valve without he biases 
intrinsic to cooperative multi-institutional studies 
that include heterogeneous populations. ~9' 2o Before 
we begin the comparative analysis of our data, some 
specific characteristics of our patient population 
should be considered: (1) we studied a group of 
middle-aged patients with moderate symptoms with 
a significant proportion of rheumatic pathologic 
conditions (Table III); (2) dysfunction of a previous 
prosthesis constituted the indication for operation in 
a large proportion of patients in each of the MVR, 
AVR, and MultiVR groups (Table III); (3) ischemic 
heart disease was the main cause of the valve disease 
in only a few patients (Table III) and associated 
revascularization procedures were not common (Ta- 
ble I); (4) an aggressive attitude against ricuspid 
pathologic onditions was maintained, with a signif- 
icant number of reparative procedures (Table I); 
and (5) oral anticoagulation therapy was prescribed 
for all patients, but the INR target value was in the 
lower range of current recommendations, m Early 
anticoagulation with intravenous odium heparin 
was not used. 
Our patients had a relatively oung mean age, 
which was comparable to that in several other 
surveys in the literature, 3' 5, 22, 23 and a prevalence of 
ischemic heart disease and coronary bypass proce- 
dures similar to that in some reports. 5'22 Our hos- 
pital mortality rates are somewhat higher than those 
reported by other investigators and are probably 
influenced by a considerable proportion of re-re- 
placement procedures and the greater prevalence of 
tricuspid valve disease in our cohort. Our overall 
long-term survival, however, is similar to the surviv- 
als that have been reported in patient populations 
with comparable demographic and clinical charac- 
teristics and better than the rates from other Amer- 
ican reviews dealing with older and sicker pa- 
tients.4, 24 The actuarial estimates of freedom from 
valve-related mortality at 5 years are, in our study, 
similar to those in most recent investigations on 
last-generation, tilting disk or bileaflet mechanical 
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prostheses. 3-5'22-24 In our experience, the overall 
survival rates at the 5-year mark are significantly 
worse than valve-related survival probabilities. This 
difference is even greater in studies done in popu- 
lations with a worse preoperative profile in terms of 
predictors for long-term prognosis, g' 24 Hence the 
ultimate fate of the patients eems to be determined 
more by cardiac nonvalvular or noncardiac ompli- 
cations than by valve-related events, which is a 
generalized finding in recent studies. 34' 19 
Our anticoagulation policy shows some differ- 
ences compared with those of other series and is 
based on the current evidence that a less intense 
anticoagulation regimen (1) should not necessarily 
be penalized by an increased number of thrombotic 
complications and (2) is linearly accompanied by a 
decreased prevalence of hemorrhagic phenome- 
nay  '26 Also, several other long-term follow-up 
studies howed a progressive reduction in the target 
INR value with time with no increase in thrombo- 
embolic rates. 3' 4 Our patients did not receive hep- 
arin early after operation and the INR target values 
were 2.5 to 3, which is lower than the value that is
customary in most units in the United States but 
which is in accordance with the current recommen- 
dations of the American College of Chest Physi- 
ciansY This different policy might explain the 
slightly higher thromboembolic rates in our study 
compared with the rates in the studies of Kratz,  3 
Khan, 4 Copeland, 23 Aoyagi, 5 and their co-workers 
on bileaflet prostheses, although the differences 
disappear when the comparison is made with earlier 
tilting disk prostheses. 24 One should also consider 
the profile of our patient population, with its rela- 
tively low mean age, and the fact that we are dealing 
with last-generation bileaflet valves. These charac- 
teristics allow a decrease in the INR target values 
while still being in the safe range, as has been 
recently shownY' 28 Also, the hemorrhagic compli- 
cations associated with anticoagulant treatment are 
usually more severe, in terms of mortality or perma- 
nent impairment, than the thromboembolic coun- 
terparts. 27 
The morbid consequences of thromboembolic 
phenomena, namely death and permanent impair- 
ment, are qually frequent in our and other authors' 
experience,3, 23 which suggests that the increase in 
the overall number of embolic phenomena observed 
with our antithrombotic policy occurs mainly at the 
expense of the number of minor episodes. 
On the other hand, anticoagulant-related h mor- 
rhagic events were few in our experience. One of our 
patients died, but we had no instance of permanent 
impairment caused by hemorrhagic omplications, 
whereas Kratz and associates 3 reported linearized 
rates for death or permanent deficit of this origin of 
0.6 + 0.2 events/100 pt-yr for AVR and 0.3 - 0.2 for 
MVR, and Copeland 23 found an overall death rate 
of this origin of 0.6 events/100 pt-yr. 
The overall clinical performance of the Carbo- 
Medics valve prosthesis is in our experience satis- 
factory at this length of follow-up and comparable to 
that of other current bileaflet devices. Thrombotic 
phenomena were in the current study still a point of 
concern, and hemorrhagic omplications, although 
low, did not completely disappear. Improvement in
anticoagulation strategies and control systems is 
essential, even with newer mechanical heart valve 
prostheses, if we want to get better esults in terms 
of the thrombosis-hemorrhage balance. 
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